Skip to content
Clinical Trials – home
Verifiedinfo

Universita Degli Studi Di Brescia

Italy Piazzale Spedali Civili 1, 25123 Brescia, Italy

  • 174 trials recruiting
  • Acute myeloid leukaemia · Dementia Alzheimer's type · Arteriosclerosis
  • Adults and children

About Specializations

Universita Degli Studi Di Brescia in Brescia, Italy specialises in clinical trials of conditions such as Acute myeloid leukaemia, Dementia Alzheimer's type, Arteriosclerosis, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Dermatologic Cancer Research

At Universita Degli Studi Di Brescia, clinical research in neoplasms focuses on skin cancer and related precancerous conditions, especially actinic keratosis and cutaneous squamous cell carcinoma. These studies are designed to assess how well treatments can reduce cancer risk, improve disease control, and support better long-term outcomes for patients.

  • Evaluating treatment effectiveness in actinic keratosis and preventing progression to invasive disease
  • Studying adjuvant therapy strategies for high-risk cutaneous squamous cell carcinoma
  • Assessing whether new approaches can improve disease-free survival after standard cancer care

This work reflects a strong interest in both early skin lesion management and more advanced cancer treatment, with the goal of improving outcomes in dermatologic oncology.

Respiratory Medicine and Critical Care Studies

Research in respiratory tract diseases at the Divisione di Pediatria includes studies of acute respiratory distress syndrome, a serious condition that can affect breathing and recovery in critically ill patients. The trials aim to explore new ways to reduce complications and improve survival-related outcomes.

  • Testing therapies intended to improve lung recovery in acute respiratory distress syndrome
  • Measuring whether treatment can increase time free from mechanical ventilation
  • Exploring options that may help prevent longer-term respiratory damage

These studies are centered on better supportive care and treatment effectiveness for patients facing severe respiratory illness.

Immune System and Rare Disease Investigations

The site also supports research into immune system processes and rare inherited conditions such as WHIM syndrome. This area of work focuses on strengthening immune function, reducing infections, and understanding whether targeted treatment can offer lasting benefit for people with complex immune disorders.

  • Examining treatments that may raise circulating neutrophil levels in WHIM syndrome
  • Assessing long-term safety and tolerability in a rare immune condition
  • Supporting better control of infections and immune-related symptoms

These trials highlight a translational approach to rare disease care, combining symptom improvement with broader immune support.

Mixed Therapeutic Research Across Pediatric and Clinical Care

Across its clinical trial portfolio, Universita Degli Studi Di Brescia is contributing to research that spans oncology, respiratory disease, skin disorders, and immunology. The studies are broadly aimed at testing new therapies, comparing treatment options, and improving how clinicians manage both common and rare diseases.

  • Comparing active treatment with placebo or standard care to clarify benefit
  • Investigating whether new interventions can improve patient outcomes and safety
  • Supporting evidence-based care for both chronic and severe conditions

With 7 trials and a large investigator network, the site shows an active commitment to advancing clinical research in multiple therapeutic areas.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Spedali Civili 125123 BresciaItaly
Recruiting now
174 trials
Conditions studied
197
Partner status
Verified

More sites in BresciaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

508 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VISUGROMAB
  • Sponsor:CatalYm GmbH
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Alexion Pharmaceuticals Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Newron Pharmaceuticals S.p.A.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).